HIV-1整合酶是由HIV病毒pol基因编码的分子量为32KD的蛋白质，是HIV病毒复制的必需酶之一，它催化病毒DNA整合入宿主染色体DNA。人类细胞中没有HIV 整合酶的类似物[1]，理论上抑制整合酶对人体副作用很小。因此HIV-1整合酶成为继HIV-1蛋白酶，逆转录酶后治疗艾滋病的富有吸引力和合理的靶标。本文综述了HIV整合酶结构，抑制剂的研究以及以HIV-1 整和酶为靶点治疗AIDS方法的最新研究进展。
HIV-1 integrase enzyme is a 32 KDa protein encoded by HIV pol gene. It is responsible for integration of viral cDNA into host chromosomal DNA, which is indispensable for HIV replication.Since there was no functional equivalent for this enzyme in human cells, inhibition of integrase will bring little side effect to human body. Thus HIV integrase has become an attractive and rational target for therapy of AIDS after reverse transcriptase and protease. This review focuses on the recent research on HIV integrase structure ,inhibitors and also new therapeutic method target at HIV-1 integrase.
李芳琼,丁倩,詹金彪. HIV-1整合酶及其抑制剂的研究进展[J]. 中国生物工程杂志, 2008, 28(1): 80-86.
Li Fang-Qiong ZHAN Jin-Biao. Progress in research on HIV-1 integrase and its inhibitors. China Biotechnology, 2008, 28(1): 80-86.
https://manu60.magtech.com.cn/biotech/CN/ 或 https://manu60.magtech.com.cn/biotech/CN/Y2008/V28/I1/80
Cited
